(BW)(MA-OXIGENE)(OXGN)(OXGN.ST) OXiGENE公司用于治疗晚期癌症的靶向肿瘤血管破坏试剂CA4P连同新生血管抑制剂Bevacizumab（商品名Avastin）接收首例Phase Ib临床实验患者

美国商业资讯2006年11月8日马萨诸塞州WALTHAM消息－－

OXiGENE, Inc. （纳斯达克股票代码：OXGN，斯德哥尔摩证券交易所交易代码：OXGN）今天宣布已经为其晚期实体瘤Phase Ib 临床实验登记了首例病患，该疗法结合了其靶向肿瘤血管破坏试剂（Vascular Disrupting Agent，简称VDA）CA4P，以及一种新生血管抑制剂Bevacizumab（商品名Avastin）。在最近的一期Science杂志(Shaked, et al, 2006) 上，带有新生血管抑制剂的VDA被描述为提供了一种强大且高度导向性的方法来抑制肿瘤增长。OXiGENE 总裁兼首席执行官Richard Chin博士对此评价表示：“我们很高兴能够为这一重要实验开始病患招募。我们相信CA4P和Avastin的组合将能够为患者带来巨大收益。病患登记同时昭显了我们迅速及时执行计划的决心。”

OXiGENE相信这一剂量递增试验是完全阐明VDA和新生血管抑制剂结合体功效和安全性的第一步。

关于OXiGENE, Inc.

OXiGENE公司是新兴的制药公司，开发治疗肿瘤和眼疾病新颖的小分子疗法。公司主要致力于备选药物的临床改进，这些药物可选择性的干扰与实体瘤增长和导致视觉缺陷相关的异常血管。OXiGENE公司致力于利用其知识产权的产品和疗法发掘专业经验来挽救病人的生命，提高病人用药的疗效。

免责声明

本新闻稿中关于OXiGEN业务的描述含有根据1995年私人证券诉讼改革法案所界定的“前瞻性声明”。 这些声明包括但不限于：CA4P 结合Avastin 在晚期实体瘤Phase Ib 临床试验过程中未来病患登记的成功和准时以及CA4P与新生血管抑制剂结合体的有效和安全性。

本前瞻性声明中的任何前瞻性陈述最终有可能是错误的。他们可能受OXiGENE公司所做出的错误的假设和公司已知或未知的风险和不确定性因素的影响，这些影响因素包括但不限于：产品开发的早期阶段；确保必要的病人的能力；现在和计划的临床试验取得成功的不确定性；正在开发的产品的安全及效用未得到确认。

因此，前瞻性声明是不受担保的，实际结果可能与预期的结果存在本质性差别。其他可能导致实际结果与前瞻性声明中的结果存在本质性差别的因素在OXiGENE公司提交给证券交易委员会的报告中有所描述，包括OXiGENE公司提交的表10-Q/8-K和10-K。但是，无论是否有新信息出现、未来发生新事件和其他事宜，OXiGENE公司不承担公开更新此前瞻性声明中信息的责任。

联系方式：OXiGENE, Inc. 投资者关系 781-547-5900

(BW)(MA-OXIGENE)(OXGN)(OXGN.ST) First Patient Enrolled in OXiGENE's Phase Ib Trial of its Lead Vascular Disrupting Agent, CA4P, in Combination with an Antiangiogenic Agent, Bevacizumab (Avastin) for the Treatment of Advanced Cancer

WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 8, 2006--

OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) today announced that the first patient has been enrolled and dosed in its Phase Ib clinical trial in advanced solid tumors, which combines its lead Vascular Disrupting Agent (VDA), CA4P, with an antiangiogenic agent, bevacizumab (Avastin). In a recent Science (Shaked, et al, 2006) publication, the combination of a VDA with an antiangiogenic agent was described as offering a powerful and highly targeted regimen for suppressing tumor growth. Dr. Richard Chin, President and CEO of OXiGENE, stated, "We are very excited to begin enrollment in this important trial. We believe that the combination of CA4P and Avastin has the potential to bring significant benefit to patients. This patient enrollment also highlights our renewed focus on executing our programs rapidly and on schedule."

OXiGENE believes that this dose escalation trial is the first step toward fully elucidating the efficacy and safety profiles of combining VDAs and antiangiogenic agents in patients.

About OXiGENE, Inc.

OXiGENE is an emerging pharmaceutical company developing novel small-molecule therapeutics to treat cancer and eye diseases. The Company's major focus is the clinical advancement of drug candidates that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property position and therapeutic development expertise to bring life saving and enhancing medicines to patients.

Safe Harbor Statement

Certain statements in this news release concerning OXiGENE's business are considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, those relating to: the success and timing of future enrollment of patients into the Phase Ib trial of CA4P in combination with Avastin in advanced solid tumors and the efficacy and safety of combining CA4P with antiangiogenic agents.

Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions OXiGENE might make or by known or unknown risks and uncertainties, including, but not limited to: the early stage of product development; the ability to secure necessary patents; uncertainties as to the future success of ongoing and planned clinical trials; and the unproven safety and efficacy of products under development.

Consequently, no forward-looking statement can be guaranteed, and actual results may vary materially. Additional information concerning factors that could cause actual results to materially differ from those in the forward-looking statements is contained in OXiGENE's reports to the Securities and Exchange Commission, including OXiGENE's reports on Form 10-Q, 8-K and 10-K. However, OXiGENE undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise.

CONTACT: OXiGENE, Inc. Investor Relations 781-547-5900